Lysosomal Storage Disorder-Pipeline Insights, 2017
[Lowest Price Guaranteed: $1,250]

Published by Delve Insight: 30 May 2017 | 84865
Related Topics: Delivery , FDA

Sorry, this report is no longer available.

We may have other suitable reports available - try Searching for Lysosomal
or contact our sales team for personal assistance: phone +44 (0)7887945155 or email bioportfolio97@gmail.com.

Introduction

DelveInsight’s, “ Lysosomal Storage Disorder-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Lysosomal Storage Disorder. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Lysosomal Storage Disorder. DelveInsight’s Report also assesses the Lysosomal Storage Disorder therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

• The report provides competitivepipeline landscape of Lysosomal Storage Disorder

• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

• Coverage of the Lysosomal Storage Disorder pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

• The report reviews key players involved in the therapeutics development for Lysosomal Storage Disorder and also provide company profiling

• The report also gives the information of dormant and discontinued pipeline projects

• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages

• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Delivery Time - 48-72 Hours

Table of Contents
for Lysosomal Storage Disorder-Pipeline Insights, 2017

List Of Tables
in Lysosomal Storage Disorder-Pipeline Insights, 2017

• Number of Products under Development for Lysosomal Storage Disorder, 2017

• Number of Products under Development by Companies

• Comparative Analysis by Filed and Phase III Products, 2017

• Comparative Analysis Phase II Products, 2017

• Comparative Analysis Phase I and IND Filed Products, 2017

• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017

• Drug Candidates Profiles

• Lysosomal Storage Disorder Assessment by Monotherapy Products

• Lysosomal Storage Disorder Assessment by Combination Products

• Lysosomal Storage Disorder Assessment by Route of Administration

• Lysosomal Storage Disorder Assessment by Stage and Route of Administration

• Lysosomal Storage Disorder Assessment by Molecule Type

• Lysosomal Storage Disorder Assessment by Stage and Molecule Type

• Lysosomal Storage Disorder Therapeutics – Discontinued Products

• Lysosomal Storage Disorder Therapeutics – Dormant Products

• Products under Development by Companies, 2017

List Of Figures, Charts and Diagrams
in Lysosomal Storage Disorder-Pipeline Insights, 2017

• Number of Products under Development for Lysosomal Storage Disorder, 2017

• Filed and Phase III Products, 2017

• Phase II Products, 2017

• Phase I and IND Filed Products, 2017

• Discovery and Pre-Clinical Stage Products, 2017

• Lysosomal Storage Disorder Assessment by Monotherapy Products

• Lysosomal Storage Disorder Assessment by Combination Products

• Lysosomal Storage Disorder Assessment by Route of Administration

• Lysosomal Storage Disorder Assessment by Stage and Route of Administration

• Lysosomal Storage Disorder Assessment by Molecule Type

• Lysosomal Storage Disorder Assessment by Stage and Molecule Type

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

84865 | DIPR2017379

Number of Pages

60

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Lysosomal Storage Disease Partnering 2010-2017
The Global Lysosomal Storage Disease Partnering Terms and Agreements since 2010 report provides unde...
01 Nov 2017 by Current Partnering USD $1,495 More Info
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Pipeline Review, H2 2017
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Pipeline Rev...
31 Oct 2017 by Global Markets Direct USD $3,500 More Info
Global Lysosomal Storage Disease Partnering 2010-2017
The Global Lysosomal Storage Disease Partnering Terms and Agreements since 2010 report provides unde...
01 Oct 2017 by Current Partnering USD $1,495 More Info
Global Lysosomal Storage Disease Partnering 2010-2017
The Global Lysosomal Storage Disease Partnering Terms and Agreements since 2010 report provides unde...
01 Sep 2017 by Current Partnering USD $1,495 More Info
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Pipeline Review, H1 2017
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Pipeline Rev...
30 May 2017 by Global Markets Direct USD $3,500 More Info
Global Lysosomal Storage Disease Partnering 2010-2017
The Global Lysosomal Storage Disease Partnering Terms and Agreements since 2010 report provides unde...
01 Apr 2017 by Current Partnering USD $1,495 More Info
Global Lysosomal Storage Disease Partnering 2010-2017
The Global Lysosomal Storage Disease Partnering Terms and Agreements since 2010 report provides unde...
01 Feb 2017 by Current Partnering USD $1,495 More Info
Global Lysosomal Storage Disease Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,495 More Info
Global Lysosomal Storage Disease Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Lysosomal Storage Disorder Global Clinical Trials Review, H2, 2015
Lysosomal Storage Disorder Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial...
23 Dec 2015 by Global Data USD $2,500 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

We Stock...